|
Ouabain
resources
DRUG INFO
Ouabain
Drug Name:
Ouabain
|
|
|
Indication: For the treatment of atrial fibrillation and flutter and heart failure
Pharmacology: Ouabain, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mechanism Of Action: Ouabain inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Ouabain also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Drug Category: Cardiotonic Agents;
Brand Names/Synonyms: Acocantherin; Astrobain; G-Strophanthin; G-Strophicor; Gratibain; Gratus Strophanthin; Kombetin; Ouabagenin L-Rhamnoside; Ouabain; Ouabain Octahydrate; Ouabain, Octahydrate; Ouabaine; Purostrophan; Rectobaina; Solufantina; Strodival; Strophalen; Strophanthin G; Strophanthin-G; Strophoperm; Strophosan; Uabaina; Uabanin
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: 4-[1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-(3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl)oxy-2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
Chemical Formula: C29H44O12
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00135
CAS Registry Number: 630-60-4
| | |
